Latest news

• ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line

  It now assumes that Teva’s fremanezumab and Eli Lilly’s galcanezumab, which remain under FDA review but should have decisions before year-end, will also be priced around the same

• Novartis, Amgen set low price for first CGRP migraine drug

  Amgen and Novartis have beaten Lilly's galcanezumab, Teva's fremanezumab and Alder's eptinezumab to market, with first-mover advantage in a market for CGRP drugs that is expected to ... Lilly is expecting the FDA to complete its review of galcanezumab in

• Amgen and Novartis migraine drug hits the mark again

  other CGRP drugs in development, a group which includes Eli Lilly's galcanezumab, Teva's fremanezumab and Alder's eptinezumab.

• Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

  hoping to add to its portfolio with new therapies for breast cancer ( abemaciclib) and migraine ( galcanezumab).

• Race to CGRP migraine drug finish line enters the final straight

  US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab. Amgen and partner Novartis are looking at getting an FDA decision on their new CGRP inhibitor drug for migraine by ... The US regulator has accepted the marketing